Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADK | P55263 | 13/20 | 0.44 |
| ▸ | SLC29A1 | Q99808 | 1/20 | 0.41 |
| ▸ | HASPIN | Q8TF76 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | GAPDH | P04406 | 1/20 | 0.32 |
| ▸ | PRMT5 | O14744 | 1/20 | 0.32 |
| ▸ | WDR77 | Q9BQA1 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25109983 | 1.00 | ADK (0.44) | ADKSLC29A1HASPINLMNAALDH1A1 | |
| SCHEMBL25109992 | 0.87 | PRMT5 (0.41) | LMNAALDH1A1PRMT5WDR77 | |
| SCHEMBL30003625 | 0.87 | PRMT5 (0.41) | LMNAALDH1A1PRMT5WDR77 | |
| SCHEMBL21682992 | 0.86 | ADK (0.42) | ADKSLC29A1HASPIN | |
| SCHEMBL21682990 | 0.86 | ADK (0.42) | ADKSLC29A1HASPIN | |
| SCHEMBL30003569 | 0.86 | ADK (0.42) | ADKSLC29A1HASPIN | |
| SCHEMBL30003551 | 0.84 | GAPDH (0.36) | ALDH1A1GAPDH | |
| SCHEMBL31123727 | 0.80 | ADK (0.44) | ADKSLC29A1HASPINLMNAALDH1A1 | |
| SCHEMBL21012864 | 0.79 | ADK (0.43) | ADKSLC29A1LMNAALDH1A1GAPDH | |
| SCHEMBL15225534 | 0.79 | ADK (0.43) | ADKSLC29A1LMNAALDH1A1GAPDH |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12173026-B2 | PRMT5 inhibitors | MERCK SHARP & DOHME LLC (US) | 2024-12-24 | — | — | US | disclosed |
| US-20230062119-A1 | USE OF BIOMARKERS IN IDENTIFYING PATIENTS THAT WILL BE RESPONSIVE TO TREATMENT WITH A PRMT5 INHIBITOR | MERCK SHARP & DOHME LLC (US) | 2023-03-02 | — | — | US | disclosed |
| US-20220363707-A1 | PRMT5 INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2022-11-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220363707-A1 | PRMT5 INHIBITORS | PRMT5, PRMT1, PRMT3 | ADK 1636/4885SLC29A1 1161/4885HASPIN 2072/4885 |
| US-12173026-B2 | PRMT5 inhibitors | PRMT5, PRMT1, PRMT3 | ADK 1636/4885SLC29A1 1161/4885HASPIN 2072/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.